- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
-
Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S
- KMID: 2512103
- Intest Res.
- 2021 Jan;19(1):71-82.
- doi: 10.5217/ir.2019.09159
Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
-
Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S
- KMID: 2512104
- Intest Res.
- 2021 Jan;19(1):83-94.
- doi: 10.5217/ir.2019.09160
Background/Aims: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal Calprotectin in Parkinson’s Disease and Multiple System Atrophy
-
Hor JW, Lim SY, Khor ES, Chong KK, Song SL, Ibrahim NM, Teh CSJ, Chong CW, Hilmi IN, Tan AH
- KMID: 2530215
- J Mov Disord.
- 2022 May;15(2):106-114.
- doi: 10.14802/jmd.21085
Objective Converging evidence suggests that intestinal inflammation is involved in the pathogenesis of neurodegenerative diseases. Previous studies on fecal calprotectin in Parkinson’s disease (PD) were limited by small sample sizes,... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402643
- Intest Res.
- 2018 Jan;16(1):17-25.
- doi: 10.5217/ir.2018.16.1.17
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402642
- Intest Res.
- 2018 Jan;16(1):4-16.
- doi: 10.5217/ir.2018.16.1.4
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
